Biosimilar insulins: a E uropean perspective
Diabetes Obesity and Metabolism2014Vol. 17(5), pp. 445–451
Citations Over TimeTop 11% of 2014 papers
Abstract
Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes the current biosimilars approved in Europe and the key clinical issues associated with the use of biosimilar insulins.
Related Papers
- → Biosimilar insulins: a E uropean perspective(2014)30 cited
- → Effectiveness of biosimilar adoption within a UK tertiary hospital: 6‐year follow‐up(2023)1 cited
- → Biosimilars markets: US and EU compared(2020)3 cited
- → Biosimilar Drugs(2012)3 cited
- → Prospects and Challenges for the Commercialization of Biosimilars: Perspectives from the EU, Japan, and the US(2016)